SOLVENTUM CORPORATION Research and Development Expense
SOLVENTUM CORPORATION (SOLV) reported Research and Development Expense of $178.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- SOLVENTUM CORPORATION research and development expense for the quarter ending 2026-06-30 was $178.00M, a 5.82% decline year-over-year.
- SOLVENTUM CORPORATION research and development expense for the quarter ending 2026-03-31 was $189.00M, a 2.07% decline year-over-year.
- SOLVENTUM CORPORATION research and development expense for the quarter ending 2025-12-31 was $175.00M, a 12.06% decline year-over-year.
- SOLVENTUM CORPORATION research and development expense for the quarter ending 2025-09-30 was $183.00M, a 3.17% decline year-over-year.
- SOLVENTUM CORPORATION research and development expense for fiscal 2025 was $739.00M, a 4.65% decline from fiscal 2024.
- SOLVENTUM CORPORATION research and development expense for fiscal 2024 was $775.00M, a 2.24% increase from fiscal 2023.
- SOLVENTUM CORPORATION research and development expense for fiscal 2023 was $758.00M, a 1.17% decline from fiscal 2022.
- SOLVENTUM CORPORATION research and development expense for fiscal 2022 was $767.00M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $178.00M 10-Q · filed 2026-08-05 | $367.00M 10-Q · filed 2026-08-05 | $542.00M derived: sum of 3 quarters · filed 2026-08-05 | $725.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $189.00M 10-Q · filed 2026-05-05 | $364.00M derived: sum of 2 quarters · filed 2026-05-05 | $547.00M derived: sum of 3 quarters · filed 2026-05-05 | $736.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $175.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $358.00M derived: sum of 2 quarters · filed 2026-02-27 | $547.00M derived: sum of 3 quarters · filed 2026-08-05 | $739.00M 10-K · filed 2026-02-27 |
| 2025-09-30 | $183.00M 10-Q · filed 2025-11-06 | $372.00M derived: sum of 2 quarters · filed 2026-08-05 | $564.00M 10-Q · filed 2025-11-06 | $764.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $189.00M 10-Q · filed 2026-08-05 | $381.00M 10-Q · filed 2026-08-05 | $581.00M derived: sum of 3 quarters · filed 2026-08-05 | $770.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $193.00M 10-Q · filed 2026-05-05 | $392.00M derived: sum of 2 quarters · filed 2026-05-05 | $581.00M derived: sum of 3 quarters · filed 2026-05-05 | $773.00M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $199.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $388.00M derived: sum of 2 quarters · filed 2026-02-27 | $580.00M derived: sum of 3 quarters · filed 2026-02-27 | $775.00M 10-K · filed 2026-02-27 |
| 2024-09-30 | $189.00M 10-Q · filed 2025-11-06 | $381.00M derived: sum of 2 quarters · filed 2025-11-06 | $576.00M 10-Q · filed 2025-11-06 | $766.00M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $192.00M 10-Q · filed 2025-08-08 | $387.00M 10-Q · filed 2025-08-08 | $577.00M derived: sum of 3 quarters · filed 2026-02-27 | $757.00M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $195.00M 10-Q · filed 2025-05-09 | $385.00M derived: sum of 2 quarters · filed 2026-02-27 | $565.00M derived: sum of 3 quarters · filed 2026-02-27 | $758.00M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $190.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $370.00M derived: sum of 2 quarters · filed 2026-02-27 | $563.00M derived: sum of 3 quarters · filed 2026-02-27 | $758.00M 10-K · filed 2026-02-27 |
| 2023-09-30 | $180.00M 10-Q · filed 2024-11-08 | $373.00M derived: sum of 2 quarters · filed 2024-11-08 | $568.00M 10-Q · filed 2024-11-08 | |
| 2023-06-30 | $193.00M 10-Q · filed 2024-08-09 | $388.00M 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | $195.00M 10-Q · filed 2024-05-10 | |||
| 2022-12-31 | $767.00M 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |
| HAEMONETICS CORP (HAE) | United States | $4.821B | 36.52 |
| Heartflow, Inc. (HTFL) | United States | $4.225B |